Vivos Therapeutics (VVOS) Enterprise Value (2019 - 2025)
Historic Enterprise Value for Vivos Therapeutics (VVOS) over the last 7 years, with Q3 2025 value amounting to -$3.1 million.
- Vivos Therapeutics' Enterprise Value rose 5087.94% to -$3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 million, marking a year-over-year increase of 5087.94%. This contributed to the annual value of -$6.3 million for FY2024, which is 28101.03% down from last year.
- Vivos Therapeutics' Enterprise Value amounted to -$3.1 million in Q3 2025, which was up 5087.94% from -$4.4 million recorded in Q2 2025.
- Over the past 5 years, Vivos Therapeutics' Enterprise Value peaked at -$1.0 million during Q3 2023, and registered a low of -$34.2 million during Q2 2021.
- Moreover, its 5-year median value for Enterprise Value was -$6.3 million (2024), whereas its average is -$9.9 million.
- In the last 5 years, Vivos Therapeutics' Enterprise Value skyrocketed by 8535.58% in 2022 and then plummeted by 53110.0% in 2024.
- Quarter analysis of 5 years shows Vivos Therapeutics' Enterprise Value stood at -$24.0 million in 2021, then surged by 85.36% to -$3.5 million in 2022, then surged by 53.31% to -$1.6 million in 2023, then plummeted by 281.01% to -$6.3 million in 2024, then surged by 50.48% to -$3.1 million in 2025.
- Its last three reported values are -$3.1 million in Q3 2025, -$4.4 million for Q2 2025, and -$2.3 million during Q1 2025.